フォン・ウィルブランド病2A型:最新情報
Omid Seidizadeh1, Luciano Baronciani2, Pier Mannuccio Mannucci3
1Internal Medicine, IRCCS Foundation Maggiore Policlinico Hospital, Milan, Italy.
Seminars in thrombosis and hemostasis
|December 26, 2025
まとめ
フォン・ウィルブランド病(VWD)2A型は、フォン・ウィルブランド因子(VWF)の欠陥を伴い、血小板接着の障害と重度の出血につながります。診断には、効果的な管理のための機能的アッセイ、マルチマー分析、および遺伝子検査が必要です。
科学分野:
- 血液学
- 分子生物学
- 遺伝学
背景:
- フォン・ウィルブランド病(VWD)は、機能不全または欠乏したフォン・ウィルブランド因子(VWF)によって引き起こされる、最も一般的な遺伝性出血性疾患です。
- 2A型VWDは、高分子量および中間分子量のVWFマルチマーの欠如に関連する、VWF依存性血小板接着の障害を特徴とする質的欠陥を表します。
研究 の 目的:
- 2A型VWDの疫学、病態生理、臨床症状、診断方法、分子基盤、および治療戦略を網羅した包括的なレビューを提供すること。
- VWF構造欠陥がマルチマーアセンブリ、タンパク質分解的切断、およびリガンド相互作用にどのように影響するかについての現在の理解を更新すること。
主な方法:
- 既存の2A型VWDに関する文献のレビュー。
- 機能的アッセイ、VWFマルチマー分析、および遺伝子検査を含む診断アプローチの分析。
- VWFバリアント機能の解明に関する分子および構造研究の検討。
主要な成果:
- 2A型VWDは、VWF活性/抗原およびコラーゲン結合/抗原比の低下と関連しています。
- 根本的な欠陥は、VWFマルチマーアセンブリの障害またはADAMTS13によるVWF切断の増加に起因します。
- 臨床的特徴には、有意な粘膜皮膚出血が含まれ、診断はサブタイプ特異的変異の遺伝的同定によって支持されます。
結論:
- 2A型VWDには、機能的、構造的、および遺伝的分析を組み合わせた多面的な診断アプローチが必要です。
- VWF欠陥の分子基盤を理解することは、標的療法の開発に不可欠です。
- 管理戦略は出血の重症度に合わせて調整され、デスモプレシンおよびVWF補充療法が含まれます。
関連する概念動画
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K
Disorders of Hemostasis
1.9K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.9K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
317
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
317
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Cardiomyopathy II: Dilated Cardiomyopathy
431
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
431


